Blood test strategy aims to keep TB patients on life-saving drug
NCT ID NCT06590428
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 19 times
Summary
This study tests whether regularly measuring the amount of linezolid in the blood can prevent people with rifampin-resistant tuberculosis from stopping the drug early due to side effects. About 280 adults who have started a linezolid-containing regimen will be randomly assigned to either standard care or drug-level monitoring. The goal is to keep patients on effective treatment for the full 6 months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DRUG-RESISTANT TUBERCULOSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Nkqubela TB Specialist Hospital
RECRUITINGEast London, Eastern Cape, 5206, South Africa
Contact
Contact
Conditions
Explore the condition pages connected to this study.